SPEAKER: So I've been lucky to use these agents both as a practicing clinician largely in patients with FH, but also leading clinical trials of patients with ASCVD. And one of the things that has been really encouraging, is that patients continue to take these drugs. I think that we learn from the statin experience that a lot of patients come off their statin within a matter of months after starting. That hasn't been the experience of PCSK9 inhibitors.

I think it's a lot to do with patient selection. It's a lot to do with education and talking to your patient, kind of really walking through that need to take this injectable drug. But to do that with the idea that it's going to lower their cholesterol very significantly, it's going to lower their risk of having cardiovascular event. I mean, the patient then buys into that concept, and that's why we've seen the really good longer term compliance kind of data that we've seen not only in the clinical trials, but also in clinical practice.